Altimmune, Inc.: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp. disclosed a stake exceeding 5% in Altimmune, Inc. via a Schedule 13G filing with the SEC (accession 0000093751-26-000611). The filing signals that the institutional investor has crossed the 5% beneficial ownership threshold in the clinical-stage biopharmaceutical company. The exact share count and percentage were not specified in the headline disclosure. The move matters because 13G filings are closely watched for signs of passive institutional accumulation in small-cap biotech names. Investors will watch for further detail on the precise size of the position and any subsequent 13G amendments.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Altimmune, Inc., State Street Corp